by Dr. Trupti Shirole on  October 10, 2015 at 5:53 AM Alternative Medicine News
 Nobel for Chinese Scientist Has Lessons for Research on Indian Folk Medicine
The Nobel Prize winner Chinese scientist Tu Youyou turned to traditional herbal medicine to develop novel malaria therapies. This should inspire India to focus on scientifically validating and promoting its rich heritage of folk medicine, suggested a health expert G. Padmanaban, former director of the Indian Institute of Science, Bengaluru.

Padmanaban said, "We have a vast repertoire of traditional medicine and these are documented in our ancient texts such as the Vedas. But we have to embrace modern science and validate the claims with hard scientific evidence. The Nobel for Tu is well deserved and should encourage India to back traditional knowledge with hard scientific data."

As an example, Padmanaban, pointed out the case of popular Indian spice turmeric and its active principal curcumin. Padmanabhan and his team have been working on a curcumin-artemisinin combination and have found it to be effective against cerebral malaria.

He said, "We have been working with curcumin as an adjunct drug with arteether (a semi-synthetic derivative of artemisinin) in animal models. Curcumin was an ideal adjunct drug to prevent and treat cerebral malaria."

Padmanaban firther added, "Use of curcumin has yielded excellent results in terms of preventing parasite recrudescence (patients coming back a few weeks after primary therapy). In addition it can also check emergence of resistance to artemisinin, since it can lower the toxicity and dosage of the primary drug. While the researchers are awaiting the Drug Controller General of India's nod to conduct efficacy trials in cerebral malaria patients, pre-clinical toxicity studies and Phase I safety studies in normal human volunteers have been completed."

Despite curcumin's potential health benefits, Padmanaban lamented that it has not been an approved drug even for a single ailment. He said, "Multinational pharmaceutical companies will not be interested since it is cheap and easily patentable. The best option would be to carry out clinical trials with curcumin as an adjunct therapy with the existing drugs and if it could be promote as a molecule for treating specific diseases."

Source: IANS

Most Popular on Medindia

More News on: